Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)

被引：6

作者：

Sakai, H. ^{[1
]}

Nishio, M. ^{[2
]}

Hida, T. ^{[3
]}

Nakagawa, K. ^{[4
]}

Nogami, N. ^{[5
]}

Atagi, S. ^{[6
]}

Takahashi, T. ^{[7
]}

Nokihara, H. ^{[8
]}

Saka, H. ^{[9
]}

Takenoyama, M. ^{[10
]}

Fujita, S. ^{[11
]}

Tanaka, H. ^{[12
]}

Takeda, K. ^{[13
]}

Satouchi, M. ^{[14
]}

Isobe, H. ^{[15
]}

Maemondo, M. ^{[16
]}

Goto, K. ^{[17
]}

Hirashima, T. ^{[18
]}

Minato, K. ^{[19
]}

Tamura, T. ^{[20
]}

机构：

[1] Saitama Canc Ctr, Thorac Oncol, Saitama, Japan

[2] Japanese Fdn Canc Res, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan

[3] Aichi Canc Ctr Hosp, Thorac Oocol, Nagoya, Aichi 464, Japan

[4] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan

[5] Natl Hosp Org, Thorac Oncol, Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[6] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Thorac Oncol, Osaka, Japan

[7] Shizuoka Canc Ctr, Thorac Oncol, Shizuoka, Japan

[8] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[9] Natl Hosp Org, Resp Med & Med Oncol, Nagoya Med Ctr, Nagoya, Aichi, Japan

[10] Kyushu Natl Canc Ctr, Thorac Oncol, Fukuoka, Japan

[11] Inst Biomed Res & Innovat, Integrated Oncol, Kobe, Hyogo, Japan

[12] Niigata Canc Ctr Hosp, Internal Med, Niigata, Japan

[13] Osaka City Gen Hosp, Med Oncol, Osaka, Japan

[14] Hyogo Canc Ctr, Thorac Oncol, Akashi, Hyogo, Japan

[15] KKR Sapporo Med Ctr, Med Oncol, Sapporo, Hokkaido, Japan

[16] Miyagi Canc Ctr, Resp Med, Natori, Miyagi 9811293, Japan

[17] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan

[18] Osaka Prefectural Med Ctr Resp & Allerg Dis, Thorac Malignancy, Osaka, Japan

[19] Gunma Prefectural Canc Ctr, Resp Med, Ohta, Gunma, Japan

[20] St Lukes Int Hosp, Thorac Canc, Tokyo, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30322-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

521

引用

页码：S110 / S111

页数：2

共 50 条

[1] Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC)
Nakagawa, Kazuhiko u
Nishio, Makoto
Hida, Toyoaki
Sakai, Hiroshi
Nogami, Naoyuki
Atagi, Shinji
Takahashi, Toshiaki
Nokihara, Hiroshi
Saka, Hideo
Takenoyama, Mitsuhiro
Fujita, Shiro
Tanaka, Hiroshi
Takeda, Koji
Satouchi, Miyako
Isobe, Hiroshi
Maemondo, Makoto
Goto, Koichi
Hirashima, Tomonori
Minato, Koichi
Tamura, Tomohide
[J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S270 - S271
[2] Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Crino, Lucio
Bronte, Giuseppe
Bidoli, Paolo
Cravero, Paola
Minenza, Elisa
Cortesi, Enrico
Garassino, Marina C.
Proto, Claudia
Cappuzzo, Federico
Grossi, Francesco
Tonini, Giuseppe
Sarobba, Maria Giuseppina
Pinotti, Graziella
Numico, Gianmauro
Samaritani, Riccardo
Ciuffreda, Libero
Frassoldati, Antonio
Bregni, Marco
Santo, Antonio
Piantedosi, Francovito
Illiano, Alfonso
De Marinis, Filippo
Tamberi, Stefano
Giannarelli, Diana
Delmonte, Angelo
[J]. LUNG CANCER, 2019, 129 : 35 - 40
[3] Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
Nishio, Makoto
Hida, Toyoaki
Atagi, Shinji
Sakai, Hiroshi
Nakagawa, Kazuhiko
Takahashi, Toshiaki
Nogami, Naoyuki
Saka, Hideo
Takenoyama, Mitsuhiro
Maemondo, Makoto
Ohe, Yuichiro
Nokihara, Hiroshi
Hirashima, Tomonori
Tanaka, Hiroshi
Fujita, Shiro
Takeda, Koji
Goto, Koichi
Satouchi, Miyako
Isobe, Hiroshi
Minato, Koichi
Sumiyoshi, Naoki
Tamura, Tomohide
[J]. ESMO OPEN, 2017, 2
[4] Maintenance chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC)
Belalcazar, A.
Santos, E. S.
Gomez, J. E.
Lopez, E.
Raez, L. E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[5] Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
Rosell, Rafael
Gonzalez-Cao, Maria
[J]. LANCET, 2021, 397 (10274): : 557 - 559
[6] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
Sankawa, Yuri
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
[7] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
Paz-Ares, Luis
Horn, Leora
Borghaei, Hossein
Spigel, David R.
Steins, Martin
Ready, Neal
Chow, Laura Quan Man
Vokes, Everett E.
Felip, Enriqueta
Holgado, Esther
Barlesi, Fabrice
Kohlhaeufl, Martin
Rodriguez, Oscar
Burgio, Marco Angelo
Fayette, Jerome
Gettinger, Scott N.
Harbison, Christopher
Dorange, Cecile
Finckenstein, Friedrich Graf
Brahmer, Julie R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
Paz-Ares, Luis
Horn, Leora
Borghaei, Hossein
Spigel, David R.
Steins, Martin
Ready, Neal
Chow, Laura Quan Man
Vokes, Everett E.
Felip, Enriqueta
Holgado, Esther
Barlesi, Fabrice
Kohlhaeufl, Martin
Rodriguez, Oscar
Burgio, Marco Angelo
Fayette, Jerome
Gettinger, Scott N.
Harbison, Christopher
Dorange, Cecile
Finckenstein, Friedrich Graf
Brahmer, Julie R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
[9] COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA
Alhammad, A.
Lecca, Garrido S.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A741 - A741
[10] Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
Gonzalez, P.
Ortega-Joaquin, N.
Provencio Pulla, M.
Garrido, C.
Echave, M.
[J]. ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →